# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ronald Reagan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML008-SYN-TD
- Date: 2001-02-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellison, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week post-fracture check, with neurology consultation for dementia staging and evening restlessness. **S**

## History of present illness

Mr. Reagan is a 90-year-old man with moderate Alzheimer's disease who returns two weeks after his first visit following repair of a right hip fracture, and is seen by neurology on the same day. Oxycodone and diphenhydramine were stopped two weeks ago. His hip aches a little when he walks, and scheduled acetaminophen keeps him comfortable. His caregivers report that he sleeps as well as before without the diphenhydramine and has been no more confused. He finished 35 days of enoxaparin last week, without bruising or bleeding. Home physical therapy continues, and he walks short distances in the house with a front-wheeled walker and standby help. He has had no falls. Grab bars, a raised toilet seat, and night lights went in after the home safety assessment, and loose rugs were taken up. Mild evening restlessness and repeated questions continue; a quiet, unhurried evening routine settles them. He takes donepezil each morning and vitamin D daily from a weekly organizer. **S**

| Element | Detail |
|---|---|
| Interval change | Mild hip ache on walking; walking a little farther with the walker |
| Medicines stopped two weeks ago | Oxycodone and diphenhydramine; no worse sleep or confusion since |
| Clot prevention | Enoxaparin finished at day 35 last week; no bleeding |
| Falls | None |
| Behavior | Mild evening restlessness and repeated questions, settled by routine |
| Function | Barthel Index 60, up from 55 two weeks ago |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Appetite good; no fever |
| Cardiovascular | Negative | No lightheadedness on standing, fainting, or calf swelling |
| Gastrointestinal | Negative | No constipation since oxycodone was stopped; no nausea on donepezil |
| Musculoskeletal | Positive | Mild right hip ache on walking, eased by acetaminophen |
| Neurological | Positive | Known memory loss, unchanged by his caregivers' account; no new weakness |
| Psychiatric | Positive | Mild evening restlessness; no hallucinations, aggression, or low mood |

6 systems reviewed. **S**

## Current medications

- Donepezil 10 mg oral tablet, one tablet by mouth daily in the morning **S**
- Acetaminophen 500 mg oral tablet, two tablets (1,000 mg) by mouth three times daily **S**
- Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/72 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 76.5 kg; BMI 22.4 kg/m². All vital signs are synthetic.

Barthel Index: 60. All results are synthetic.

## Change since baseline

- Barthel Index: 55 at baseline, 60 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, pleasant, and sociable |
| Cardiovascular | Regular rhythm at 62 per minute; no murmur; no ankle edema |
| Musculoskeletal | Right hip incision healed; no calf tenderness or swelling; stands with arm help and walks with a front-wheeled walker and standby help, steady |
| Neurological | Oriented to person, not to date; follows one-step commands; no focal weakness |
| Psychiatric | Cheerful; no agitation during the visit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Dementia due to Alzheimer's disease, moderate (FAST stage 5)** (F02.B0). Neurology confirms moderate Alzheimer's disease at FAST stage 5, in keeping with the MoCA of 11 two weeks ago. The evening restlessness is mild and responds to routine, and there has been no delirium since diphenhydramine was stopped. Heart rate 62 on donepezil, with no fainting. **S**
   - Continue donepezil 10 mg each morning.
   - Keep the evening routine; no antipsychotic or sedative.
   - Memantine is not added for now, to keep medicines few during recovery from the fracture; revisit at the yearly review.
   - MoCA, FAST stage, and ADL and IADL scores yearly on the CMID schedule.
2. **Osteoporosis with a healing right hip fragility fracture** (M80.051D). Healing well. Pain is controlled without opioids, and enoxaparin is complete. **S**
   - Continue scheduled acetaminophen and home physical therapy.
   - Continue cholecalciferol 2,000 units daily and calcium from food.
   - DXA, 25-hydroxyvitamin D, calcium, and kidney function at the three-month visit, then zoledronic acid if they allow.
3. **History of falling** (Z91.81). No falls since the fracture. Fall risk stays high with dementia, age, and recovery from the fracture. **S**
   - Walker and standby help for all walking; supervision at night.
   - Keep the home safety changes in place.
4. **Advance care planning**. Advance care planning was discussed today with the patient taking part as he was able. The health care agent was confirmed and goals of care were discussed. **S**
   - Complete a POLST form at the three-month visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Pain assessment | Every visit | Completed today | Mild hip ache on walking; scheduled acetaminophen only; no opioid since the first visit |
| Examination | Physical and occupational therapy progress | Every visit | Completed today | Barthel Index 60, up from 55; home therapy continues |
| Examination | CDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressure | Every primary care visit after the fracture | Completed today | No falls; steady with the walker and standby help; no lightheadedness on standing |
| Examination | Timed Up and Go | When home therapy ends, then yearly or with a change | Up to date | 24 seconds two weeks ago; repeat when home therapy ends |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Grab bars, raised toilet seat, and night lights installed; rugs removed |
| Examination | Driving safety | At diagnosis and yearly | Not indicated | His caregivers provide all transport |
| Medication safety | Venous thromboembolism prophylaxis | At least 10 to 14 days, up to 35 days after surgery | Completed today | Enoxaparin finished at day 35 last week; no bleeding or calf swelling |
| Medication safety | AGS Beers Criteria medication review | Every visit and at each transition of care | Completed today | No opioid, antihistamine, or sedative since the first visit |
| Medication safety | Cholinesterase inhibitor benefit and tolerability | Each follow-up | Completed today | Donepezil continued: heart rate 62, no fainting, nausea, or weight loss |
| Medication safety | Antipsychotic appropriateness review | Every visit while on an antipsychotic | Not indicated | Not on an antipsychotic; neurology advises none |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild evening restlessness and repeated questions; no hallucinations or aggression |
| Survey | Cognitive test (MoCA), FAST stage, and ADL and IADL scores | At diagnosis, then yearly | Completed today | Neurology confirms FAST stage 5. MoCA 11 of 30, Barthel Index 55, and Lawton IADL 1 of 8 at the first visit two weeks ago; next full set in a year |
| Survey | Depression screen (GDS-15) | At 1, 3, and 6 months after the fracture; yearly in dementia | Up to date | GDS-15 4 at the one-month visit two weeks ago; next at three months |
| Survey | Caregiver assessment with the Zarit Burden Interview | At diagnosis, then every 6 to 12 months | Up to date | 41 of 88 two weeks ago; repeat at six months |
| Laboratory | TSH and vitamin B12 | At the diagnosis of dementia; repeat only as indicated | Not indicated | The dementia workup belongs to the original diagnosis years ago; TSH was normal two weeks ago |
| Imaging | Brain MRI | Once at diagnosis; repeat only with an acute change | Not indicated | No new neurologic signs |
| Laboratory | APOE genotype, amyloid biomarkers, and baseline MRI for anti-amyloid therapy | Before starting lecanemab or donanemab | Not indicated | Moderate dementia (MoCA 11) is outside the eligibility range for anti-amyloid therapy |
| Laboratory | 25-hydroxyvitamin D after repletion | Repeat after repletion | Due | 16 ng/mL two weeks ago; recheck at three months before zoledronic acid |
| Imaging | DXA after the fracture | At the first outpatient visit if not previously diagnosed | Due | Not obtained at the first visit; by plan it is done at the three-month visit with the first infusion, after vitamin D repletion, so treatment is not delayed |
| Referral | Fracture Liaison Service | During the hospital stay, with follow-up for a year | Deferred | No fracture liaison referral is on record from the hospital stay, a deviation from the protocol. Primary care is carrying out the same steps (vitamin D repletion, DXA, and zoledronic acid at three months) and tracks them here, so no step has been lost |
| Referral | Neurology consultation | At stage changes or when behavior changes | Completed today | Seen today for staging, donepezil review, and evening restlessness |
| Referral | Caregiver support services | Ongoing | Completed today | Home health aide in place; weekly respite and Alzheimer's Association support services arranged |
| Self-management | Advance care planning | At diagnosis, yearly, and at stage changes | Completed today | Health care agent confirmed and goals of care discussed; POLST form at the three-month visit |
| Self-management | Calcium intake from food and supplements | Ongoing; target 1,000 to 1,200 mg a day | Completed today | Reviewed with his caregivers; calcium-rich food at each meal |

## Goal progress

- Walk household distances with a walker and supervision, with a Barthel Index of 75 or more, by the three-month visit. In progress; target 2001-04-14. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more by three months, then the first zoledronic acid infusion. In progress; target 2001-04-14. **S**
- No further falls through the six-month visit. In progress; target 2001-07-14. **S**
- Lower the spouse's Zarit Burden Interview score by at least 10 points by six months. In progress; target 2001-07-14. **S**
- Document a health care agent, goals of care, and a POLST form by the three-month visit. In progress; target 2001-04-14. **S**

## Guideline basis

- Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021), American Academy of Orthopaedic Surgeons
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (Osteoporosis International)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024), Alzheimer's Association
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026), Aether Forge

## Follow-up

- Three-month post-fracture visit in seven weeks, with DXA, laboratory tests, and zoledronic acid if they allow. **S**
- Next scheduled visit 2001-04-14: three-month post-fracture visit with bone density testing and zoledronic acid. **S**
